Validation of Noninvasive Tracer Kinetic Analysis of 18F-Florbetaben PET Using a Dual–Time-Window Acquisition Protocol
暂无分享,去创建一个
Osama Sabri | Santiago Bullich | Norman Koglin | Andrew W Stephens | Henryk Barthel | Georg A Becker | Susan De Santi | Aleksandar Jovalekic | S. de Santi | O. Sabri | H. Barthel | G. Becker | N. Koglin | S. Bullich | Aleksandar Jovalekic | A. Stephens
[1] Jeih-San Liow,et al. Linearized Reference Tissue Parametric Imaging Methods: Application to [11C]DASB Positron Emission Tomography Studies of the Serotonin Transporter in Human Brain , 2003, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[2] John Seibyl,et al. Impact of Training Method on the Robustness of the Visual Assessment of 18F-Florbetaben PET Scans: Results from a Phase-3 Study , 2016, The Journal of Nuclear Medicine.
[3] Ana M. Catafau,et al. OPTIMAL REFERENCE REGION TO MEASURE LONGITUDINAL AMYLOID-BETA CHANGE WITH 18F-FLORBETABEN PET , 2016, Alzheimer's & Dementia.
[4] John Seibyl,et al. Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study , 2015, Alzheimer's & Dementia.
[5] John Seibyl,et al. Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome study , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[6] Rik Ossenkoppele,et al. Longitudinal Amyloid Imaging Using 11C-PiB: Methodologic Considerations , 2013, The Journal of Nuclear Medicine.
[7] A. Lammertsma,et al. Forward to the Past: The Case for Quantitative PET Imaging , 2017, The Journal of Nuclear Medicine.
[8] Masanori Ichise,et al. PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.
[9] John Seibyl,et al. Optimized classification of 18F-Florbetaben PET scans as positive and negative using an SUVR quantitative approach and comparison to visual assessment , 2017, NeuroImage: Clinical.
[10] Davide Poggiali,et al. A new integrated dual time-point amyloid PET/MRI data analysis method , 2017, European Journal of Nuclear Medicine and Molecular Imaging.
[11] H. Braak,et al. Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.
[12] John Seibyl,et al. Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.
[13] G. Searle,et al. The Simplified Reference Tissue Model: Model Assumption Violations and Their Impact on Binding Potential , 2015, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[14] M Slifstein,et al. Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. , 2000, Nuclear medicine and biology.
[15] Nick C Fox,et al. Acceleration of cortical thinning in familial Alzheimer's disease , 2011, Neurobiology of Aging.
[16] Steven Staelens,et al. Validation of the Semiquantitative Static SUVR Method for 18F-AV45 PET by Pharmacokinetic Modeling with an Arterial Input Function , 2017, The Journal of Nuclear Medicine.
[17] A. Danek,et al. Evaluation of early-phase [18F]-florbetaben PET acquisition in clinical routine cases , 2016, NeuroImage: Clinical.
[18] Vincent J. Cunningham,et al. Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.
[19] Osama Sabri,et al. Cerebellar Amyloid-β Plaques: How Frequent Are They, and Do They Influence 18F-Florbetaben SUV Ratios? , 2016, The Journal of Nuclear Medicine.
[20] Matthias L. Schroeter,et al. Early [18F]florbetaben and [11C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer’s disease , 2016, European Journal of Nuclear Medicine and Molecular Imaging.